Bristol-Myers Squibb Company today announced that Part 1 a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® plus low-dose Yervoy ® met the co-primary endpoint of overall survival, demonstrating ...

Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels Median duration of response for patients ...